Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

May 3, 2016

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Solid TumorsCNS Tumors
Interventions
DRUG

Entrectinib

TRKA/B/C, ROS1, and ALK inhibitor

Trial Locations (27)

10065

Memorial Sloan Kettering Cancer Center, New York

13385

Hôpital de la Timone, Oncologie Pédiatrique, Marseille

19104

Children's Hospital of Philadelphia, Philadelphia

20133

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

21205

Johns Hopkins University, Baltimore

28009

Hospital Infantil Universitario Nino Jesus, Madrid

30322

Egleston Children's Hospital at Emory University Atlanta, Atlanta

38105

St. Jude Children'S Research Hospital, Memphis

43205

Nationwide Children's Hospital, Columbus

60637

University of Chicago, Chicago

63110

Washington University,St. Louis Children's Hospital, St Louis

69120

Universitaetsklinikum Heidelberg, Heidelberg

69373

Centre Leon Berard, Lyon

77030

Texas Children's Cancer and Hematology Center, Houston

80045

Children's Hospital Colorado, Aurora

84113

Primary Children's Hospital, Salt Lake City

92123

Rady Childrens Hospital, San Diego

94158

UCSF Benioff Children's Hospital, San Francisco

97239

Oregon Health & Science Uni, Portland

200082

Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai

92093-0706

University of California San Diego, La Jolla

02215

Dana Farber Cancer Institute, Boston

M5G 1X8

The Hospital for Sick Children, Toronto

Unknown

Beijing Children's Hospital, Capital Medical University, Beijing

00000

Hong Kong Children's Hospital, Hong Kong

SW3 6JJ

Royal Marsden Hospital (Sutton), London

NE1 4LP

Royal Victoria Infirmary, Newcastle upon Tyne

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02650401 - Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options | Biotech Hunter | Biotech Hunter